ReviewMedical science monitor : international medical journal of experimental and clinical research2025
Advances in Positron Emission Tomography/Computed Tomography for Diagnosing and Managing Primary Posterior Uveal Melanoma.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma is a common primary intra-ocular malignancy in adults. It is a highly aggressive cancer that can spread to other regions of the body. Thus, early detection and appropriate treatment are critical for patient survival. Currently, we cannot imagine modern oncological diagnostics without positron emission tomography/computed tomography (PET/CT). Although PET/CT is commonly used in cancer care, it is not widely used for eye cancer. However, as technology advances, more eye specialists are using PET/CT to stage tumors before treatment, to predict how patients will respond to treatment, and to monitor their progress to assess treatment effectiveness. In this review, we cover the aspects of this technology in managing posterior uveal melanoma and describe the advantages of PET/CT in providing better information about tumors and their responses to applied treatment. We also describe the role of PET/CT in distinguishing among posterior uveal melanomas, benign lesions such choroidal nevus, and other primary or metastatic intra-ocular malignancies. We also discuss the role of PET/CT in staging metastatic choroidal melanoma. As technology continues to evolve, the role of PET/CT in comprehensive management of eye cancer is likely to expand, offering enhanced insights into tumor characteristics and treatment outcomes. This article reviews the role of PET/CT in diagnosing, staging, and monitoring treatment outcomes in patients with primary posterior uveal (choroidal and ciliary body) melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.